Loading...

Regeneus Ltd

RGS.AX•ASX
Healthcare
Biotechnology
A$0.01
A$0.003(33.33%)

Regeneus Ltd (RGS.AX) Company Profile & Overview

Explore Regeneus Ltd’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Regeneus Ltd (RGS.AX) Company Profile & Overview

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. Its lead platform technology includes Progenza, a multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing. Regeneus Ltd was incorporated in 2007 and is headquartered in Paddington, Australia.

SectorHealthcare
IndustryBiotechnology
CEOKarolis Rosickas

Contact Information

https://regeneus.com.au
1300 995 098
2 Paddington Street, Paddington, NSW, 2021

Company Facts

IPO DateSep 19, 2013
CountryAU

Frequently Asked Questions

;